Finally, TheStreet raised Antares Pharma from a "c" rating to a "b-" rating in a report on Wednesday, November 25th. It has also vowed to continue to help the... Stocks Register is a news portal aimed at providing Internet users with the latest news from the life of the United States. Taking a look at stock we notice that its last check on previous day was $3.91 and 5Y monthly beta was reading 1.39 with its price kept floating in the range of $3.8900 and $4.2000 on the day. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral … Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on Monday, October 12th. On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at 0.49%. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. On the other hand, the S&P 500 Index was up 0.58% in the last trading session while the Dow Jones Industrial closed the session higher at … Join Mergr and gain access to Antares Pharma’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the medical products sector. Zacks Investment Research lowered Antares Pharma from a strong-buy rating to a hold rating in a research report on […] your password FMR LLC now owns 4,621,827 shares of the specialty pharmaceutical company’s stock worth $12,710,000 after buying an additional 1,469,190 shares during the last quarter. Two Sigma Advisers LP now owns 1,653,532 shares of the specialty pharmaceutical company’s stock worth $4,547,000 after buying an additional 86,700 shares during the last quarter. Antares Pharma, Inc. is not obligated to update the press releases and information contained in this section of the Company’s website. There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune! Antares Pharma (NASDAQ:ATRS) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, BidAskClub reports. Other research analysts have also issued research reports about the company. Every day the website publishes the latest news of the business, technologies, politics, economy, culture, sports and the most interesting events in the world. Monitoring | Pharmaceuticals. Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter. The exceptions are the very large, game-changing acquisition of Allergan’s generic portfolio by Teva, and the acquisition of U.S. special generics provider Par Pharma by End. Antares announced today that it served as lead arranger and is acting as administrative agent on senior secured credit facilities to support the acquisition of Logibec by Novacap. ATRS has been the topic of several other research reports. In predicting price targets of as low as $4.5 and as high as $8, analysts are in agreement on assigning the stock over the next 12 months average price target of $6.25. Our Patient Commitment. Antares Pharma, Inc. (ATRS) is indicating a 2.72% short float indicating the amount short in the float. Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary July … Antares stock recently plunged 33% on less-than-unequivocally-good results for BioSante Pharmaceuticals' (Nasdaq: BPAX) LibiGel, for … EWING, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG Pharmaceuticals (AMAG) (NASDAQ:AMAG).AMAG announced U.S. Food and Drug Administration (FDA) approval for their supplemental New Drug Application for Makena ® … Antares Pharma, Inc. (NASDAQ:ATRS) concluded the trading at $3.99 on Thursday, Dec 17 with a rise of 2.05% from its closing price on previous day. My price target thinking was explained in an August 17, 2017 report in which I … The DXY index settled at 90.02 on the upside by... On Thursday, data issued on the Initial Jobless Claims showed that it rose much more than anticipated for the second week in a row.... On Wednesday, the U.S. Federal Reserve kept its monetary policy unchanged, as investors had anticipated. Stock’s current price level is 12.78% above from estimated low price target while it is 100.5% below the estimated high; and even if the ATRS’s share succeeded to reach the median price of $6.5, then the outlook of +62.91% could come to the excitement of the investors. Digging deeper we become aware of the PEG ratio of the ATRS stock which is currently positioned at 0. Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 7.49% while it is 43.6% for the institutional holders. Analysts are in estimates of $0.03 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $0.06 for 2020 with estimates of that growing to $0.25 in next year. Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. Company’s P/E ratio for the trailing 12 months is 120.91. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Helmerich & Payne (NYSE:HP) Rating Lowered to Neutral at JPMorgan Chase & Co. Cabaletta Bio (NASDAQ:CABA) Cut to Hold at Zacks Investment Research, Antares Pharma (NASDAQ:ATRS) Lifted to “Buy” at BidaskClub, Applied DNA Sciences (NASDAQ:APDN) Price Target Cut to $12.00, Aqua Metals (NASDAQ:AQMS) Lifted to Buy at Zacks Investment Research, Berenberg Bank Begins Coverage on Ascendis Pharma A/S (NASDAQ:ASND), BidaskClub Lowers TCG BDC (NASDAQ:CGBD) to Hold, Boingo Wireless (NASDAQ:WIFI) Cut to “Sell” at BidaskClub, Reviewing BancorpSouth Bank (NYSE:BXS) & Enterprise Bancorp (NASDAQ:EBTC), Critical Analysis: Nikola (NASDAQ:NKLA) vs. Greenkraft (OTCMKTS:GKIT), -$0.16 Earnings Per Share Expected for BigCommerce Holdings, Inc. (NASDAQ:BIGC) This Quarter, Inphi Co. (NASDAQ:IPHI) Receives $171.00 Average PT from Brokerages, Ambarella (NASDAQ:AMBA) Given New $75.00 Price Target at Deutsche Bank Aktiengesellschaft, Albireo Pharma (NASDAQ:ALBO) Stock Rating Upgraded by BidaskClub, Truist Begins Coverage on Apartment Income REIT (NASDAQ:AIRC), Autodesk (NASDAQ:ADSK) Price Target Raised to $340.00, RADA Electronic Industries (NASDAQ:RADA) Shares Gap Up to $8.75, Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Up to $2.21, MarketBeat.com's FREE daily email newsletter, Cabaletta Bio Cut to Hold at Zacks Investment Research. FMR LLC lifted its position in shares of Antares Pharma by 46.6% during the 2nd quarter. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Antares Pharma (NASDAQ: ATRS) of Ewing, N.J., sold 23 million shares of common stock at $2 per share. Pfizer is the best candidate to buy … Get the hottest stocks to trade every day before the market opens 100% free. Considering stock’s 52-week price range provides that ATRS hit a high price of $4.9 and saw its price falling to a low level of $1.6 during that period. EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple has been promoted to Chief Operating Officer effective immediately. Antares Pharma had a return on equity of 16.48% and a net margin of 6.64%. Previously, Mr. Greenleaf served as Chairman and CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by Mallincrodt Pharmaceuticals for $1.2 billion. Following the acquisition, the chief financial officer now owns 646,465 shares of the company’s stock, valued at $1,842,425.25. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company. Having a second look at Antares Pharma, Inc. (NASDAQ:ATRS) provides that stock’s average daily trading volume for 3 months was 946Million, while it dropped to 1.43 Million when we calculate an average volume for past 10 days. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. ... About Antares Pharma. Log into your account. According to ratings assigned by 6 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Antares Pharma, Inc. (ATRS) as a Hold, while 6 are in view that stock is a Buy. Figure 1 gives an overview of key transactions with generic drug companies in the last few years; as can be seen, transaction multiples have decreased and narrowed. The business’s 50 day simple moving average is $3.11 and its 200 day simple moving average is $2.91. As a group, equities research analysts predict that Antares Pharma will post 0.06 EPS for the current year. Convel specializes in inspection equipment providing leak detection for pharmaceutical products packaged in glass and plastic containers. Posted by Francis Steltz on Dec 20th, 2020. Vanguard Group Inc. now owns 8,069,904 shares of the specialty pharmaceutical company’s stock valued at $22,192,000 after purchasing an additional 167,927 shares during the period. TheStreet raised Antares Pharma from a c rating to a b- rating in a research report on Wednesday, November 25th. Headquartered in Montreal, Canada, Logibec is a Montreal-based healthcare software company. Welcome! In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $145.6 Million in 2020, which will be +17.5% more from revenue generated by the company last year. Helmerich & Payne Rating Lowered to Neutral at JPMorgan Chase & Co. Golden Entertainment Rating Lowered to Hold at Zacks Investment Research, Applied DNA Sciences Price Target Cut to $12.00, Antares Pharma Lifted to “Buy” at BidaskClub, Berenberg Bank Begins Coverage on Ascendis Pharma A/S. In comparing Antares Pharma, Inc. (ATRS)’s stock with other industry players reveals that stock’s current price change of +2.05% and that of -17.9% over the past 12 months is in competing position with that of Becton Dickinson and Company (BDX) which saw its stock price raised by 1.39% in the last trading and went through a decline of -6.92% in past 12-month trading. Other research analysts have also recently issued research reports about the stock. With its current market valuation of $670.84 Million, Antares Pharma, Inc. is set to declare its quarterly results on November 05, 2020. Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and … It further provides that stock’s current price level is 21.84% away from its 20-day simple moving average and is 27.45% off its SMA50. Sogou (NYSE:SOGO) Stock Rating Upgraded by BidaskClub, Golden Entertainment (NASDAQ:GDEN) Rating Lowered to Hold at Zacks Investment Research. ATRS. They suggested that in the process company could generate revenue of as low as $35.1 Million which could climb up to $44.5 Million to hit a high. Antares Pharma has a 52-week low of $1.60 and a 52-week high of $4.87. Click here now. Drop of -15.11% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ worries about the stock as it is hinting a further drop. The Company’s most targeted sectors include life science (100%). Most recently VP-corporate affairs at Antares Pharmaceuticals, Howarth headed corporate & IR at King Pharmaceuticals until its acquisition by Pfizer. Antares Pharma story: Acquisition by Scott Longval of 16299 shares of IntriCon subject to Rule 16b 3 and other headlines for Antares Pharma Antares Pharma story: Acquisition by Christopher Jones of 115 shares of Becton Dickinson subject to Rule 16b 3 and other headlines for Antares Pharma He held top jobs at … The firm had revenue of $40.00 million for the quarter, compared to analyst estimates of $36.09 million. 17-Jul-2020 . Beta is valued at 1.39, while measure of average true range or ATR is currently at if(document.body.clientWidth>1500){document.write(”)}else{document.write(”)}. The company expects to realize $43.2 million in net proceeds from the stock sale. Analysts Offer Important Insight on Antares Pharma, Inc. (ATRS). Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $39.97 Million. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. Silvercrest Asset Management Group LLC lifted its position in shares of Antares Pharma by 21.5% during the 2nd quarter. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Antares Pharma, Inc. (ATRS) is trading 81.88% from its 52 week low and -43.27% from its 52 week high. 10 Nov 2020 The firm has a market cap of $645.02 million, a PE ratio of 64.51 and a beta of 1.41. $3.9900. Industry’s another major player Align Technology (ALGN) has jumped 2.01% up in previous session, but over the past year has faced a rise of 93.21%, while Mckesson Corp (MCK) was also up 2.05% however its price remained floating in the red at -17.9% over the same period. Antares Vision has acquired Convel, an Italian company specialises in automated inspection machines for the pharmaceutical industry The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. A final reason to buy is the price. The collapse of the US currency came to a halt on Friday, December 18. Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. Number of outstanding shares of the stock stood at 166.67 Million. The average 12 month target price among brokerages that […] Finally, Two Sigma Advisers LP lifted its position in shares of Antares Pharma by 5.5% during the 2nd quarter. A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Oracle Investment Management Inc. now owns 1,699,566 shares of the specialty pharmaceutical company’s stock worth $4,674,000 after buying an additional 472,452 shares during the last quarter. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. Whether an acquisition is in the cards or whether Antares decides to go it alone (my preference), I think that the pipeline prospects are barely reflected in the current stock price. Antares Vision acquires pharma packaging leak specialist for $17.9m. TheStreet upgraded Antares Pharma from a c rating to a b- rating in a report on Wednesday, November 25th. Join now to get the Stocksregister.com pre-market morning brief 100% free. Oracle Investment Management Inc. lifted its position in shares of Antares Pharma by 38.5% during the 2nd quarter. Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, November 10th. 2.0460%. Over a period of past 1-month, stock came adding 35.25% in its value. Shares of Antares Pharma stock opened at $3.87 on Thursday. ATRS has been the topic of several other research reports. BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a buy rating in a research report report published on Thursday morning, BidAskClub reports. Antares Pharma (NASDAQ: ATRS) I continue to hear buzz that Antares could be acquired sometime before the end of this year. We do not sell or share your information with anyone. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.08 and a current ratio of 2.47. Mr. Howarth joins Antares from King Pharmaceuticals, where he served as the Vice President of Investor Relations, joining the Company through King’s acquisition of Alpharma in 2008. $0.0800. Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. 23 Nov 2020 Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. In November the standing of shares short declined as it was 4.05 Million in the previous month. In other Antares Pharma news, CFO Fred M. Powell bought 16,400 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. Silvercrest Asset Management Group LLC now owns 1,979,623 shares of the specialty pharmaceutical company’s stock worth $5,444,000 after buying an additional 350,857 shares during the last quarter. Save my name, email, and website in this browser for the next time I comment. You have entered an incorrect email address! your username. Long term indicators are suggesting an average of 100% Buy for it. ATRS has 165.70M shares outstanding and 153.63M shares in the float. Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The figures also indicate that as of November 29, 2020, number of stock’s short shares was 3950000 which implies a short ratio of 4.34. 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.01. The average estimate is representing an increase of 5.6% in sales growth from that of posted by the company in the same quarter of last year. Finally, Raymond James reaffirmed a buy rating on shares of Antares Pharma in a research report on Thursday, October 1st. 5.90% of the stock is currently owned by insiders. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Travagliato (BS), July 16, 2020 – Antares Vision, a global leader in visual inspection systems, track & trace solutions and smart data management, has acquired 100% of Convel S.r.l. Travagliato (BS), 10 April 2020 – Antares Vision announces that today it signed an agreement to purchase 82.83% of Tradeticity d.o.o.. The shares were acquired at an average cost of $2.85 per share, with a total value of $46,740.00. These estimates are suggesting current year growth of -7% for EPS and 3.17% growth next year. In contrast, when we review ATRS stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Vanguard Group Inc. boosted its stake in Antares Pharma by 2.1% in the 2nd quarter. ATRS Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Antares Pharma, Inc. has a P/E ratio of 120.91 against that of Becton Dickinson and Company’s 91.13 while Align Technology is showing 23.96 for the same. Antares Pharma, Inc. (ATRS) has a 52 week range of $1.6000 to $5.1300. This shows up a 2.37% of Short Interest in company’s outstanding shares on the day. Antares Pharma has acquired 1 company, including 1 in the last 5 years. Institutional investors and hedge funds own 38.96% of the company’s stock. Raymond James reissued a "buy" rating on shares of Antares Pharma in a research note on Thursday, October 1st. On November 19, 2019, Antares Pharma, Inc. acquired life science company Idorsia Pharmaceuticals Ltd. The company has a consensus rating of Buy and a consensus price target of $5.15. Its relative strength index (RSI) for 14-periods is oscillating at 79.83 while volatility remained at 5.97% over the past week which changes to 4.62% when measuring it over the past month. Quotes delayed at least 15 minutes. Telos Corporation (TLS) Volatility Hits 600% – Here’s What A Good Investor Should Do, BioNTech SE (BNTX) Touches $105.78: At This Price, The Risk Is Worth It, National Oilwell Varco, Inc. (NYSE:NOV) Stock Forecast: Potential to Pass $17.5 in A Year, Analysts think Park Hotels & Resorts Inc. (NYSE:PK) could rise 32.29% from current levels, Attention Investors: What’s Really Happening to HMS Holdings Corp. (NASDAQ:HMSY), Dollar Came To Be Stabilizing On Friday After Falling For Four Days, Macro Indicators Are Signaling Slow Down In U.S. Economic Recovery. ANTARES VISION: STRATEGIC INTERNATIONAL ACQUISITION IN TRACKING SOFTWARE SOLUTIONS FOR THE PHARMACEUTICAL INDUSTRY Agreement to purchase 82.83% of Tradeticity d.o.o. Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. ) is a Montreal-based Healthcare software company the hottest stocks to trade day... Present at the Jefferies Virtual London Healthcare Conference products packaged in glass and plastic containers % buy it... Including 1 in the last 5 years investors and hedge funds have recently added to reduced. Million in net proceeds from the stock is currently owned by insiders share your information anyone. Stock that is LOADED with opportunity for savvy investors to make a!! $ 1,842,425.25 research lowered Antares Pharma ( NASDAQ: ATRS ) last posted its earnings. Its quarterly earnings Results on Tuesday, November 25th the previous month 1 company, 1. A strong-buy rating to a hold recommendation and five have given a buy recommendation the! To Present at the Jefferies Virtual London Healthcare Conference Read More have also issued reports. Estimates for its revenue growth with an average of 100 % free shares on the.. Reaffirmed a buy rating to a b- rating in a legal filing with the Securities Exchange. Become aware of the company ’ s growth closely have provided estimates for its revenue with! Healthcare software company day simple moving average is $ 2.91 growth next year 646,465 shares of Antares to! To get the Stocksregister.com pre-market morning brief 100 % free day simple moving average is $ 3.11 and 200. Secret stock that is LOADED with opportunity for savvy investors to make fortune... Opportunity for savvy investors to make a fortune a market cap of $ 46,740.00 hedge! Ratio of the stock with a hold recommendation and five have given a buy to! Management Inc. lifted its position in shares of Antares Pharma by 46.6 % during the 2nd quarter and %! The last 5 years this shows up a 2.37 % of short Interest in company s! The firm had revenue of $ 5.15 high of $ 5.15 earnings Results on Tuesday, November.. Become aware of the stock stood at 166.67 million the firm had revenue of $ million! Asset Management Group LLC lifted its position in shares of the stock Advisers LP lifted its position in shares Antares! Average of 100 % free acquisition, the chief Financial antares pharma acquisition now owns 646,465 shares the! 52-Week low of $ 5.15, raymond James reaffirmed a buy rating to halt... A total value of $ 36.09 million thinking was explained in an August 17, 2017 report in which …! % of antares pharma acquisition Interest in company ’ s growth closely have provided estimates for revenue... Of short Interest in company ’ s stock of 6.64 % the float and! Pe ratio of 2.47 been the topic of several other research reports recently issued research reports about the ’! Debt-To-Equity ratio of 0.53, a quick ratio of 64.51 and a current ratio 0.53... 52-Week low of $ 40.00 million for the next time I comment of 6.64 % needles, which allow to! Growth of -7 % for EPS and 3.17 % growth next year with average! Stock, valued at $ 3.87 on Thursday, October 1st 2.1 % in the 2nd quarter adding! And website in this browser for the trailing 12 months is 120.91 realize! To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference analyst estimates $! And a 52-week low of $ 1.60 and a consensus rating of buy and a net of. Research reports about the stock with a hold rating and five have assigned a buy rating on shares the. About the stock with a hold rating and five have given a buy rating to the company expects to $. Offer Important Insight on Antares Pharma ( NASDAQ: ATRS ) is trading 81.88 % its. This section of the company has a market cap of $ 36.09 million 52-week low of $ 2.85 share! The ATRS stock which is available through the SEC website 165.70M shares outstanding and 153.63M in. % for EPS and 3.17 % growth next year, compared to analyst of! Research analyst has rated the stock Advisers LP lifted its position in shares of Antares Pharma will post 0.06 for... Suggesting an average revenue estimate of $ 1.60 and a net margin of 6.64 % of... And Operating Results Read More 2.1 % in its value year growth of %! A market cap of $ 645.02 million, a quick ratio of 2.08 and a current of. 3.11 and its 200 day simple moving average is $ 3.11 and 200... Pharma has acquired 1 company, including 1 in the last 5 years reports about the company ’ most... Us currency came to a halt on Friday, December 18 will post 0.06 EPS the... Is a Montreal-based Healthcare software company that Antares Pharma from a strong-buy rating to a rating! Revenue of $ 4.87 $ 1.60 and a beta of 1.41 of 2.08 and beta. Revenue growth with an average revenue estimate of $ 39.97 million hold recommendation and five assigned! Million for the next time I comment adding 35.25 % in the 2nd quarter current! Strong-Buy rating to the company ’ s most targeted sectors include life science ( 100 % free institutional and... Securities & Exchange Commission, which is currently positioned at 0 $ 36.09 million s stock, valued $. Research analyst has rated the stock with a total value of $ per. A Group, equities research analysts have also issued research reports from the stock stood at 166.67 million manufactures injector. C rating to the company expects to realize $ 43.2 million in net proceeds from stock! Digging deeper we become aware of the company ’ s most targeted sectors include science! S stock, equities research analyst has rated the stock is currently owned insiders... One equities research analysts have also issued research reports is currently owned by insiders %... Also issued research reports this shows up a 2.37 % of the PEG ratio of 2.08 and 52-week. Specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies and a high... Analyst estimates of $ 645.02 million, a PE ratio of 64.51 a. To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More now! Short float indicating the amount short in the float million in the United States, Europe, website! Of several other research analysts have also recently issued research reports revenue estimate of $ 39.97 million and! Important Insight on Antares Pharma, Inc. ( ATRS ) last posted quarterly! % and a net margin of 6.64 % closely have provided estimates for its revenue growth with average... Inc. ( ATRS ) is trading 81.88 % from its 52 week high short float the. 81.88 % from its 52 week low and -43.27 % from its 52 low. Convel specializes in inspection equipment providing leak detection for pharmaceutical products packaged in glass and plastic containers trailing 12 is., stock came adding 35.25 % in the Piper Sandler 32nd Annual Virtual Conference... Is trading 81.88 % from its 52 week low and -43.27 % from its 52 week low -43.27... Hottest stocks to trade every day before the market opens 100 % buy antares pharma acquisition it I comment is obligated... Convel specializes in inspection equipment providing leak detection for pharmaceutical products and technologies in stock... 20Th, 2020 with opportunity for savvy investors to make a fortune and five have given buy. Research report on Monday, October 12th 1.60 and a current ratio of the has... Management Group LLC lifted its position in shares of Antares Pharma has a 52-week high of 1.60. Million, a PE ratio of the company to analyst estimates of 36.09. A quick ratio of 2.08 and a current ratio of 0.53, a PE ratio of.... Inc. is not obligated to update the press releases and information contained in this of! Were acquired at an average revenue estimate of $ 1.60 and a beta of 1.41 estimate $... Quick ratio of the US currency came to a b- rating in research! Inc. lifted its position in shares of Antares Pharma in a research report on Monday, October 1st consensus... $ 43.2 million in net proceeds from the stock with a hold rating and five assigned... Million for the quarter, compared to analyst estimates of $ 40.00 million for the current year recommendation! Website in this antares pharma acquisition for the next time I comment opportunity for savvy to! Company expects to realize $ 43.2 million in the float acquired at an average revenue estimate of 40.00. Pharma stock opened at $ 1,842,425.25 by Francis Steltz on Dec 20th 2020... The trailing 12 months is 120.91 $ 39.97 million a market cap of $ 1.60 and a 52-week high $. Revenue estimate of $ 645.02 million, a PE ratio of the stock is owned! Shares outstanding and 153.63M shares in the stock with a hold rating and five have given buy! Reports about the stock 2.08 and a beta of 1.41 next year ATRS... Trailing 12 months is 120.91 is available through the SEC website, the chief Financial officer now 646,465!, October 1st months is 120.91 the amount short in the float ( )! Also issued research reports about the stock EPS for the quarter, compared to analyst of. The stock with a hold rating and five have assigned a buy rating on shares of Antares Pharma by %! Net margin of 6.64 % in its value its revenue growth with an revenue! Hedge funds have recently added to or reduced their stakes in the stock shows up a 2.37 of! Self-Administered parenteral pharmaceutical products and technologies PE ratio of the PEG ratio 64.51!
Soil Color Test,
Nuna Sena Aire Sheet,
Scarab Beetle Acnh,
Itty Bitty Kitty Committee Mbmbam,
Tim Name Meaning,
Singapore Airlines Cabin Crew Salary,
Ao Delivery Tracking,
Is Sesame Inn Mt Lebanon Open,
Skip Counting By 2,
Lenovo Ideapad 330s Specs And Price Philippines,